Indication

Epidermolysis bullosa

Epidermolysis bullosa encompasses a heterogeneous group of rare, predominantly inherited mechanobullous disorders defined by marked epithelial fragility of the skin and mucous membranes. Read more about Epidermolysis bullosa

2 drugs 2 manufacturers

Advertisement

Drugs that treat it

Common Epidermolysis bullosa therapies.

Showing 1–2 of 2 drugs

Filter & compare in the drug finder →Opens the drug finder with Epidermolysis bullosa preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Epidermolysis bullosa.

Epidermolysis bullosa encompasses a heterogeneous group of rare, predominantly inherited mechanobullous disorders defined by marked epithelial fragility of the skin and mucous membranes.

Pathophysiologically, genetic mutations disrupt structural adhesion proteins within the epidermis or basement membrane zone, impairing tolerance to mechanical shearing forces.

This structural defect leads to separation of tissue layers, resulting in painful blister formation, erosions, and chronic ulcerations provoked by minimal friction or minor trauma.

Although clinical severity ranges widely, presentation typically manifests in neonates or infants and can progress to severe complications, including extensive scarring, joint contractures, esophageal strictures, chronic infections, and an elevated risk of aggressive squamous cell carcinoma.

Personalize your experience

Follow Epidermolysis bullosa and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it